APA (7th ed.) Citation

Ständer, S., Yosipovitch, G., Legat, F. J., Reich, A., Paul, C., Simon, D., . . . Kwatra, S. G. (2024). Efficacy and safety of nemolizumab in patients with moderate to severe prurigo nodularis: The OLYMPIA 1 randomized clinical phase 3 trial. JAMA dermatology, 161(2), . https://doi.org/10.1001/jamadermatol.2024.4796

Chicago Style (17th ed.) Citation

Ständer, Sonja, et al. "Efficacy and Safety of Nemolizumab in Patients with Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial." JAMA Dermatology 161, no. 2 (2024). https://doi.org/10.1001/jamadermatol.2024.4796.

MLA (9th ed.) Citation

Ständer, Sonja, et al. "Efficacy and Safety of Nemolizumab in Patients with Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial." JAMA Dermatology, vol. 161, no. 2, 2024, https://doi.org/10.1001/jamadermatol.2024.4796.